NITIN P AMDARE

Dr. NITIN P AMDARE

Albert Einstein College of Medicine, Bronx, New York, USA
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2024 in Biology
Verified
Journal Article
Open access
PDF file
AMAnkita Mitra
Ankita Mitra
AKANOOP KUMAR
ANOOP KUMAR
NITIN P AMDARENITIN P AMDARE
NITIN P AMDARE
Rajiv PathakRajiv Pathak
Rajiv Pathak
Cancer immune evasion represents a leading hallmark of cancer, posing a significant obstacle to the development of successful anticancer therapies. However, the landscape of cancer treatment has significantly evolved, transitioning into the era of immunotherapy from conventional methods such as surgical resection, radiotherapy, chemotherapy, and targeted drug therapy. Immunotherapy has emerged as a pivotal component in cancer treatment, harnessing the body’s immune system to combat cancer and offering improved prognostic outcomes for numerous patients. The remarkable success of immunotherapy has spurred significant efforts to enhance the clinical efficacy of existing agents and strategies. Several immunotherapeutic approaches have received approval for targeted cancer treatments, while others are currently in preclinical and clinical trials. This review explores recent progress in unraveling the mechanisms of cancer immune evasion and evaluates the clinical effectiveness of diverse immunotherapy strategies, including cancer vaccines, adoptive cell therapy, and antibody-based treatments. It encompasses both established treatments and those currently under investigation, providing a comprehensive overview of efforts to combat cancer through immunological approaches. Additionally, the article emphasizes the current developments, limitations, and challenges in cancer immunotherapy. Furthermore, by integrating analyses of cancer immunotherapy resistance mechanisms and exploring combination strategies and personalized approaches, it offers valuable insights crucial for the development of novel anticancer immunotherapeutic strategies.

1 October 2015 in Journal of Digestive Diseases
Verified
Journal Article
Closed access
PDF file
VKVISHAL KHATRI
VISHAL KHATRI
NITIN P AMDARENITIN P AMDARE
NITIN P AMDARE
ATAaditya Tarnekar
Aaditya Tarnekar
KGKalyan Goswami
Kalyan Goswami
MRMaryada Venkata Rami Reddy
Maryada Venkata Rami Reddy

10 September 2015 in Scandinavian Journal of Immunology
Verified
Journal Article
Closed access
PDF file
GAGandhirajan Anugraha
Gandhirajan Anugraha
JMJayaprakasam Madhumathi
Jayaprakasam Madhumathi
PPPrabhu Rajaiah Prince
Prabhu Rajaiah Prince
PPParasurama Jawaharlal Jeya Prita
Parasurama Jawaharlal Jeya Prita
VKVISHAL KHATRI
VISHAL KHATRI
PKPerumal Kaliraj
Perumal Kaliraj

26 September 2016 in Journal of Helminthology
Verified
Journal Article
Closed access
PDF file
NITIN P AMDARENITIN P AMDARE
NITIN P AMDARE
VKVISHAL KHATRI
VISHAL KHATRI
RYR.S.P. Yadav
R.S.P. Yadav
ATA. Tarnekar
A. Tarnekar
KGK. Goswami
K. Goswami
MRM.V.R. Reddy
M.V.R. Reddy
Epidemiological and experimental evidence has supported the concept of using helminths as alternative bio-therapeutic agents in the treatment of type 1 diabetes (T1D). In the current study, two filarial proteins, recombinant Wuchereria bancrofti L2 (rWbL2) and Brugia malayi abundant larval transcript 2 (rBmALT-2) have been investigated, individually and in combination, for their therapeutic potential in streptozotocin (STZ)-induced T1D. The rWbL2 and rBmALT-2 proteins, when administered individually or in combination, have resulted in lowering of the blood glucose levels and reducing the incidence of T1D in mice. In addition, these proteins have led to reduced lymphocytic infiltration and decreased islet damage and inflammation. The curative effect was found to be associated with the suppression of release of tumour necrosis factor-α (TNF-α) and interferon-γ (IFN-γ), and increased production of interleukin (IL)-4, IL-5 and IL-10 cytokines by the splenocytes of the diabetic mice. Insulin-specific IgG1 and antigen-specific IgE antibodies were found to be elevated in the sera of mice treated with rWbL2 and rBmALT-2 proteins. From the findings in this study, it can be envisaged that both of these filarial immunomodulatory proteins have the potential to ameliorate T1D by altering the regulatory immune responses.

1 July 2021 in Journal of Biological Chemistry
Verified
Journal Article
Open access
NITIN P AMDARENITIN P AMDARE
NITIN P AMDARE
Anthony PurcellAnthony Purcell
Anthony Purcell
TDTeresa P. DiLorenzo
Teresa P. DiLorenzo
Type 1 diabetes (T1D) is a T cell-mediated autoimmune disease that affects the insulin-producing beta cells of the pancreatic islets. The nonobese diabetic mouse is a widely studied spontaneous model of the disease that has contributed greatly to our understanding of T1D pathogenesis. This is especially true in the case of antigen discovery. Upon review of existing knowledge concerning the antigens and peptide epitopes that are recognized by T cells in this model, good concordance is observed between mouse and human antigens. A fascinating recent illustration of the contribution of the nonobese diabetic mouse in the area of epitope identification is the discovery of noncontiguous CD4+ T cell epitopes. This novel epitope class is characterized by the linkage of an insulin-derived peptide to, most commonly, a fragment of a natural cleavage product of another beta cell secretory granule constituent. These so-called hybrid insulin peptides are also recognized by T cells in patients with T1D, although the precise mechanism for their generation has yet to be defined and is the subject of active investigation. Although evidence from the tumor immunology arena documented the existence of noncontiguous CD8+ T cell epitopes, generated by proteasome-mediated peptide splicing involving transpeptidation, such CD8+ T cell epitopes were thought to be a rare immunological curiosity. However, recent advances in bioinformatics and mass spectrometry have challenged this view. These developments, coupled with the discovery of hybrid insulin peptides, have spurred a search for noncontiguous CD8+ T cell epitopes in T1D, an exciting frontier area still in its infancy.

21 April 2017 in Immunologic Research
Verified
Journal Article
Closed access
PDF file
CIChristiana Immanuel
Christiana Immanuel
ARAparnaa Ramanathan
Aparnaa Ramanathan
MBMalathi Balasubramaniyan
Malathi Balasubramaniyan
VKVISHAL KHATRI
VISHAL KHATRI
NITIN P AMDARENITIN P AMDARE
NITIN P AMDARE
KPKaliraj Perumal
Kaliraj Perumal